What is Nascent Biotech, Inc. (NBIO) stock price today?

Nascent Biotech, Inc. (NBIO) is currently trading at $0.00.

What is NBIO P/E ratio?

Nascent Biotech, Inc.'s P/E ratio is -0.04. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is NBIO return on equity (ROE)?

Nascent Biotech, Inc.'s return on equity (ROE) is 268.93%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Nascent Biotech, Inc.'s market cap?

Nascent Biotech, Inc. has a market capitalization of $103330.

OTC · Biotechnology

Nascent Biotech, Inc. (NBIO) Stock

$0.00 OTC: NBIO Healthcare

Valuation

Metric	Value
Price	$0.00
Market Cap	$103330
P/E Ratio	-0.04
P/B Ratio	-0.36
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$0.13
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	268.93%
ROA	-854.34%
ROCE	868.81%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.48
Current Ratio	0.31

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$0	$1.0M	$1.0M	$0	$0
Operating Profit	$-3.0M	$-1.0M	$0	$-2.0M	$-2.0M
Net Profit	$-4.0M	$-1.0M	$0	$-3.0M	$-2.0M
EPS	$-0.12	$-0.01	$0.00	$-0.02	$-0.01
Op Margin	—	-186.7%	-45.7%	—	—

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$0	$1.0M	$0	$0	$1.0M
Total Liabilities	$3.0M	$1.0M	$1.0M	$2.0M	$1.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$0	$0	$0	$0	$0

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$-1.0M	$-1.0M	$0	$-2.0M	$-1.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$0	$0	$0	$0	$0
Free Cash Flow	$-1.0M	$-1.0M	$0	$-2.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.28
FCF Yield	-1147.84%
Quick Ratio	0.68
Interest Coverage	-5.79
Return 1Y	-70.00%
Return 3Y	-99.17%
Return 5Y	-99.37%

Ownership

Insiders Held21.51%

Institutions Held0.00%

Institutions Float Held0.00%

Institutional Holder	Shares	Report Date
Cubic Asset Management, LLC	105,000	2024-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BSYIBioSyntech, Inc.	$0.00	—	0.00	$229033	0.00%
CHNXFChitogenX Inc.	$0.01	+0.00%	-0.23	$627628	0.00%
CWWBFPlant-Based Investment Corp.	$0.00	—	0.00	$275	0.00%
FCHSFirst Choice Healthcare Solutions, Inc.	$0.01	+0.00%	-0.04	$296625	0.00%
PZOOPazoo, Inc.	$0.00	—	0.00	$26882	0.00%

About Nascent Biotech, Inc.

Nascent Biotech, Inc., a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma. This drug also targets numerous epithelial cancers, including those affecting the lung, breast, colon, brain, and pancreas. Additionally, the company is advancing MultiPharm, its proprietary technology platform, which holds promise for applications in cancer therapy, diabetes, autoimmune disorders, and transplantation. The company's headquarters are situated in Vero Beach, Florida.

Nascent Biotech, Inc. (NBIO) stock trades at $0.00 with a market capitalization of $103330. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.04, reflecting a net loss over the last twelve months, a negative price-to-book of -0.36, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.13, and currently trades 100.0% below its 52-week high.

On profitability, Nascent Biotech, Inc. generates a return on equity (ROE) of 268.93% (not meaningful, as shareholders' equity is negative), return on capital employed of 868.81%.

Official website: www.nascentbiotech.com